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Abstract The infectious agent in prion diseases consists
of an aberrantly folded isoform of the cellular prion protein
(PrP
c), termed PrP
Sc, which accumulates in brains of
affected individuals. Studies on prion-infected cultured
cells indicate that cellular cholesterol homeostasis inﬂu-
ences PrP
Sc propagation. Here, we demonstrate that the
cellular PrP
Sc content decreases upon accumulation of
cholesterol in late endosomes, as induced by NPC-1 knock-
down or treatment with U18666A. PrP
c trafﬁcking, lipid
raft association, and membrane turnover are not signiﬁ-
cantly altered by such treatments. Cellular PrP
Sc formation
is not impaired, suggesting that PrP
Sc degradation is
increased by intracellular cholesterol accumulation. Inter-
estingly, PrP
Sc propagation in U18666A-treated cells was
partially restored by overexpression of rab 9, which causes
redistribution of cholesterol and possibly of PrP
Sc to the
trans-Golgi network. Surprisingly, rab 9 overexpression
itself reduced cellular PrP
Sc content, indicating that PrP
Sc
production is highly sensitive to alterations in dynamics of
vesicle trafﬁcking.
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Introduction
Spongiform neurodegeneration is a pathological hallmark
of prion diseases, a group of rare and inevitably fatal dis-
orders of man and animals. Among these are Creutzfeldt-
Jakob disease (CJD) in humans and bovine spongiform
encephalopathy (BSE) in cattle, with the latter giving rise
to the zoonotic appearance of variant CJD (vCJD). One
speciﬁc characteristic of prion diseases is that the infec-
tious agents appear to consist exclusively of an abnormally
folded isoform of the cellular prion protein PrP
c, termed
PrP
Sc [1–3]. PrP
c is a sialoglycoprotein expressed mainly
in the central nervous system [4]. It is attached to the
outer leaﬂet of the plasma membrane by a glycosyl-phos-
phatidyl-inositol (GPI) anchor (reviewed in [5]). In a
posttranslational process the mainly a-helical PrP
c is con-
verted into PrP
Sc, which has a high b-sheet content and
accumulates within brains of affected individuals [6, 7].
For cellular conversion of PrP
c into PrP
Sc several pre-
mises need to be fulﬁlled. First, expression of PrP
c is
absolutely necessary [8]. Second, localization of PrP
c at the
cell surface [9, 10] and its proper conformation [11, 12] are
required. As a GPI-anchored protein, PrP
c and also PrP
Sc
are found in lipid rafts [13, 14], which are membrane
microdomains rich in cholesterol and sphingolipids. Due to
selective localization of proteins in lipid rafts and spatial
proximity, rafts serve as platforms for controlled protein-
protein interactions and for initiation of signaling events
[15]. For the formation of lipid rafts, free intracellular
cholesterol is necessary. The content of free cholesterol
within cells is tightly regulated by endogenous synthesis,
uptake via low density lipoprotein (LDL) receptors, and the
level of esteriﬁcation, which enables storage of cholesterol
in cytoplasmic lipid droplets. Within the central nervous
system, neurons downregulate their endogenous cholesterol
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and released by astrocytes bound to lipoproteins [16]. Upon
receptor-mediated endocytosis, cholesterol is released from
its transport protein in endosomes and is partially recycled
to the plasma membrane, to the trans-Golgi network
(TGN), or to the endoplasmic reticulum (ER) [17]. One
protein involved in this recycling is NPC-1, a late endo-
somal/lysosomal transmembrane protein that harbors a
putative sterol sensing domain [18]. It appears to be
involved in the vesicular transport of LDL-derived cho-
lesterol to the ER and the plasma membrane [19].
Mutations in NPC-1 lead to abrogation of this pathway and
to accumulation of free cholesterol and other metabolites
such as glycosphingolipids in the late endocytic pathway,
resulting in Niemann-Pick type C disease (NPC), a fatal
autosomal recessive neurodegenerative disorder [20].
Mechanistically, NPC-1 appears to interact with choles-
terol-containing vesicles to mediate their retrograde
transport. Mutations within the protein appear to impair
ﬁssion of NPC-1-positive vesicles from cholesterol-laden
organelles leading to accumulation of cholesterol [19].
In prion-infected cells, depletion of cholesterol by
inhibition of its synthesis reduces PrP
Sc in the neuronal cell
lines GT-1 or N2a infected with RML prions [21, 22]. This
treatment has been shown to perturb lipid raft formation
and can lead to a block of PrP
c transport to the plasma
membrane [23]. Extraction of membrane cholesterol by
methyl-b-cyclodextrin [24], ﬁlipin [25], or complexation of
membrane cholesterol by amphotericin B [26] also reduced
the PrP
Sc content of cultured cells. When the signal peptide
for GPI anchoring of PrP
c is replaced by different trans-
membrane domains to alter the membrane distribution of
PrP
c and to prevent its association with lipid rafts, these
mutant PrPs were not converted into PrP
Sc in persistently
prion-infected cells [21, 27], supporting the importance of
lipid raft localization for prion conversion. In vivo, the
cholesterol synthesis inhibitor simvastatin prolonged
incubation times of prion disease in mice [28, 29]; how-
ever, this effect is probably due to neuroprotective actions
of the drug [29, 30]. Amphotericin B and its less toxic
derivative MS-1809 both inhibit prion disease progression
although the effect depends on the prion strain used for
infection, and the drugs appear to be more effective against
BSE prions than scrapie prions [31, 32].
Most of the studies performed on the relationship
between cholesterol and PrP
Sc generation focused on the
impact of an inhibited cholesterol synthesis or of alterations
in plasma membrane cholesterol levels, accompanied by
perturbations of lipid rafts. However, the role of cholesterol
recycling in PrP
Sc propagation is only poorly understood.
For example, blocking this pathway induces alterations in
the subcellular distribution of lipid rafts [33, 34], which
could affect PrP
Sc biogenesis. Furthermore, cells that
accumulate cholesterol, e.g., CHO cells with mutations in
the NPC-1 gene or ﬁbroblasts derived from NPC-1 patients,
show defects in vesicle transport due to immobilization of
rab proteins on membranes enriched in cholesterol [35].
Thus, alterations caused by such conditions might sub-
sequently inﬂuence PrP
Sc formation in persistently infected
cells. Therefore, the aim of our study was to elucidate
whether cholesterol accumulation in the late endocytic
pathway interferes with cellular prion infection. To achieve
cholesterol accumulation, NPC-1 knock-down using small
interfering RNA (siRNA) and the compound U18666A,
which is commonly used to phenocopy mutations in the
NPC-1 gene and which leads to cholesterol accumulation
within several hours of treatment [36–38], were used.
Under both conditions, PrP
Sc accumulation was reduced in
prion-infected cells in a dose- and time-dependent manner,
due to increased degradation of PrP
Sc. Interestingly, rab 9
overexpression partially restored the negative effects of
cholesterol accumulation on PrP
Sc propagation. Our data
provide novel insights into the relationship between cho-
lesterol homeostasis and PrP
Sc formation and suggest that
recycling of cholesterol and possibly also of PrP
Sc is nec-
essary to sustain its persistent propagation in prion-infected
neuronal cells.
Materials and methods
Reagents
Proteinase K and Pefabloc proteinase inhibitor were
obtained from Roche Diagnostics, (Mannheim, Germany).
Immunoblotting was done using the enhanced chemilumi-
nescenceblottingtechnique(ECLplus)fromGEHealthcare
(Buckinghamshire, UK). The monoclonal anti-PrP antibody
(mAb) 4H11 and polyclonal antibody (pAb) A7 have been
described [39]. Polyclonal anti-NPC-1 antibody and NPC-1
siRNA were purchased from Abcam (Cambridge, UK) and
Santa Cruz (Heidelberg, Germany),respectively.Secondary
antibodies for immunoﬂuorescence were Cy2- or Cy3-
conjugated immunoglobulins obtained from Dianova
(Hamburg, Germany). Poly-L-lysine, baﬁlomycin A, anti-
b-actin antibody, and U18666A were from Sigma (Deis-
enhofen,Germany).ProteinA-Sepharosewasobtainedfrom
GE Healthcare, sulfo-NHS-biotin was from Pierce (Bonn,
Germany). Cell culture media and solutions were obtained
from Invitrogen (Karlsruhe, Germany).
Cell culture and treatment of cells
The cell lines 3F4-N2a, stably overexpressing a 3F4-tagged
murine PrP, and ScN2a have been described [40]. GT-1
[41] and SN56 were subcloned prior to infection of single
3980 S. Gilch et al.clones with prion strain 22L-infected mouse brain
homogenate (ScGT1 and ScSN56, respectively). Cells
were kept in Opti-MEM (Invitrogen, Karlsruhe, Germany)
containing 10% fetal bovine serum and penicillin/strepto-
mycin. Treatment with U18666A was performed as
indicated. Media were changed every other day, and fresh
substances were added at each medium change.
Transient transfection of cells with plasmids and siRNA
Transient transfections of ScN2a cells with pEGFP-rab9
and pcDNA3.1 (control) were done using Fugene 6 trans-
fection reagent (Roche, Mannheim, Germany) according
to manufacturer’s instructions. Treatment with U18666A
was started 24 h post transfection. For transfection of
ScN2a cells with siRNA, Lipofectamine 2000 (Invitrogen,
Karlsruhe, Germany) was used. Twenty nanomoles of
NPC-1 or ns siRNA was added for 24 h; after 2 days, lysis
of cells and PK digestion were performed.
Detergent solubility assay
Cells were lysed in lysis buffer as described for immuno-
blot analysis. Postnuclear cell lysates (without PK
treatment or following PK (20 lg/ml) digestion) were
supplemented with proteinase inhibitors (aprotinin, Pefab-
loc and PMSF) and N-lauryl sarcosine to 1%, and
ultracentrifuged in a Beckman TL-100 table ultracentrifuge
for 1 h at 40,000 rpm (100,000 g; TLA-45 rotor; 4C).
Supernatant fractions (S soluble fraction) were precipitated
with ﬁve volumes of methanol, pellet fractions (P insoluble
fraction) were resuspended in 50 ll of TNE and analyzed
in immunoblot assays.
PIPLC digestion
For PIPLC treatment, cells were used at about 80% con-
ﬂuency. After 2 washes with PBS, 200 mU of PIPLC
(Sigma, Deisenhofen, Germany) were added in 4 ml
serum-free DME medium and incubated for 4 h at 37C.
The cells were washed with PBS, lysed as described for
immunoblotting, and following methanol precipitation,
analyzed by immunoblot.
Surface biotinylation and immunoprecipitation
Cells were treated for 2 days with U18666A (3 lg/ml).
After washing the cells twice with PBS, sulfo-NHS-biotin
(250 lg/ml in PBS) was added for 10 min on ice. After
removal of biotin, cells were chased for 60 min at 37C
(-/? U18666A) or kept on ice (0 min). Then one plate
each of U18666A-treated or mock-treated cells was incu-
bated with trypsin for 10 min on ice; a second plate was
left without trypsin treatment. Trypsin digestion was ter-
minated by addition of soybean trypsin inhibitor. All cells
were lysed and PrP was immunoprecipitated with pAb A7
as described [42]. Immunoprecipitated PrP was separated
by SDS-PAGE followed by immunoblot, and biotinylated
PrP was visualized using HRP-streptavidin. Signals of the
60 min time point of three experiments were densitomet-
rically analyzed (ImageQuant TL; GE Healthcare) and
evaluated statistically (GraphPad Prism software). Intra-
cellular PrP levels (? trypsin) were expressed as
percentage of total PrP represented by PrP
c signals without
trypsin digestion.
Flotation assay for detergent-resistant microdomains
For the isolation of detergent-resistant microdomains
(DRM) or lipid rafts, 3 9 10
7 cells were solubilized in
400 ll lysis buffer (NaCl 150 mM, Tris–HCl pH 7.5
25 mM, EDTA 5 mM, and Triton-X 100 1%) and incu-
bated on ice in the cold room for 30 min. The cell lysate
was mixed with Nycodenz 70% in TNE (NaCl 150 mM,
Tris–HCl pH 7.5 25 mM, EDTA 5 mM) to a ﬁnal con-
centration of 35% Nycodenz and loaded into an
ultracentrifuge tube. This fraction was overlaid by a dis-
continuous Nycodenz gradient formed by 200-ll fractions
of Nycodenz solutions with concentrations of 25, 22.5, 20,
18, 15, 12, and 8%. After ultracentrifugation (200,000 g,
4h ,4 C, Beckmann TLS55 rotor), 200-ll fractions were
collected from the top to the bottom of the gradient and
precipitated with ﬁve volumes of methanol. After centri-
fugation for 30 min at 3,500 rpm, the pellets were
resuspended in TNE and an aliquot of each fraction was
analyzed by immunoblot. For identiﬁcation of lipid rafts,
an aliquot of each fraction was subjected to dot blot anal-
ysis using HRP-conjugated cholera toxin B (Ctx B). Ctx B
binds to the glycosphingolipid GM-1, which is a marker for
lipid rafts.
Indirect immunoﬂuorescence assay and confocal
microscopy
Cells were seeded on poly-L-Lysine-coated glass cover
slips (Marienfeld, Germany) at low density 1–3 days prior
to staining. Cells were washed twice in cold PBS and ﬁxed
in 4% paraformaldehyde for 30 min at room temperature.
After sequential treatments with NH4Cl (50 mM in 20 mM
glycine), Triton-X 100 (0.3%), and gelatin (0.2%) for
10 min each at room temperature, primary antibodies were
added at a 1:100 dilution in PBS and incubated for 30 min
at room temperature. After three washes in PBS, Cy2- or
Cy3-conjugated secondary antisera (1:100 dilution in PBS)
were applied for 30 min at room temperature. Slides were
mounted in anti-fading solution (5% propyl gallate in 70%
Cholesterol recycling and PrP
Sc propagation 3981glycerol; 100 mM Tris–HCl, pH 9.0) and kept dry at
-20C. Confocal laser scanning microscopy was done
using a Zeiss (Go ¨ttingen, Germany) LSM510 confocal
microscope.
Results
Inhibition of cholesterol recycling reduces PrP
Sc
in persistently prion-infected cultured cells
For many years it has been well established that cellular
cholesterol metabolism plays an important role for PrP
Sc
propagation. Inhibition of HMG-CoA reductase or other
enzymes involved in cholesterol synthesis or application of
compounds that bind or extract free membrane-bound
cholesterol such as amphotericin B can signiﬁcantly reduce
cellular PrP
Sc conversion or even prolong incubation time
of prion disease in animal models. However, the impact of
cholesterol membrane distribution and trafﬁcking has not
been investigated in detail so far.
Following endocytosis of LDL-cholesterol via the LDL
receptor and its dissociation from LDL, a large amount of
free cholesterol is recycled back to the plasma membrane.
OneproteinimplicatedinthistransportisNPC-1.Therefore,
one way to inhibit cholesterol transportin cultured cells isto
knock-down NPC-1 expression by transfection of cells with
siRNA. In line with this, we transiently transfected RML-
infected N2a cells (ScN2a) with siRNA targeting NPC-1
mRNA or non-silencing (ns) siRNA (Fig. 1). The efﬁciency
of the knock-down was analyzed by immunoﬂuorescence
assay using an anti-NPC-1 antibody (Fig. 1a). In cells
transfected with ns siRNA, a strong vesicular staining was
observed (left image), whereas no speciﬁc ﬂuorescence
signalwasdetectableincellstransfectedwithNPC-1siRNA
under identical immunoﬂuorescence conditions (right
image). The inset shows the image excited with higher
voltage and here, in single cells, residual ﬂuorescence sig-
nals were detectable. This proves that NPC-1 siRNA very
efﬁciently silenced the target gene. Similar results were
obtained by immunoblot assay using an anti-NPC-1 anti-
body (Suppl. Fig. 1a).
Next, the effect of NPC-1 knock-down on cellular PrP
Sc
content was analyzed. Again, ScN2a cells were transiently
transfected with ns or NPC-1 siRNA (Fig. 1b). To support
Fig. 1 Knock-down of NPC-1 drastically reduces PrP
Sc. a ScN2a
cells were transiently transfected with non-silencing (ns) siRNA or
siRNA targeting NPC-1 mRNA. Two days post transfection, cells
were stained with anti-NPC-1 antibody and Cy2-conjugated anti-
rabbit IgG. Staining was visualized by confocal laser scanning
microscopy, using identical immunoﬂuorescence settings. The inset
shows the image of cells transfected with NPC-1 siRNA excited with
higher voltage to demonstrate presence of cells. b Transient
transfections of ScN2a cells were performed in triplicate with ns
siRNA or NPC-1 siRNA. Two days after transfection, cells were
lysed and lysates were treated with (?PK) or without (-PK) PK.
SDS-PAGE and immunoblot were performed, and for detection of
PrP, monoclonal antibody 4H11 was used. To conﬁrm equal loading,
the immunoblot was reprobed with an antibody against b-actin (lower
panel; -PK). c Quantiﬁcation and statistical analysis of the effect of
NPC-1 knock-down on PrP
Sc propagation. ScN2a cells transfected
transiently with ns or NPC-1 siRNA were lysed 2 days post
transfection. The amount of PrP
Sc upon PK digestion detected by
immunoblot was densitometrically evaluated. The value for PrP
Sc in
ns siRNA transfected cells was set to 100%; the amount in NPC-1
siRNA transfected cells was expressed as a percentage thereof. For
statistical analysis, results of four independent experiments were used.
Two out of four experiments were performed in duplicate and
triplicate, respectively, and of these, the average percentage of PrP
Sc
in relation to the control (ns siRNA) was used for statistical analysis
(*** P\0.005; t-test)
c
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performed several times, including triplicate assay. Two
days post transfection, cells were lysed, an aliquot was
digested with PK, and all lysates were analyzed by
immunoblot. In samples without PK digestion (lanes 1–6)
no major differences in total PrP signals were detectable.
In contrast, PK-treated samples from cells transfected with
ns siRNA harbored high amounts of PrP
Sc (lanes 7–9;
N-terminally trimmed PrP; un-, mono-, and di-glycosylated
forms), whereas in NPC-1 siRNA-transfected cells, PrP
Sc
was not detectable under these conditions. Reprobing the
membrane with anti-b-actin antibody conﬁrmed equal
loading. Statistical analysis of the results of four indepen-
dent experiments revealed a highly signiﬁcant reduction in
PrP
Sc levels in cells transfected with NPC-1 siRNA
(Fig. 1c). However, if transiently transfected cells were
lysed 3 or 4 days post transfection with siRNAs, PrP
Sc
signals in NPC-1 siRNA-transfected cells increased again
at day 3 and were almost equal to the signal in control cells
at day 4 after transfection (Suppl. Fig. 1b). This could be
explained by the only transient knock-down of NPC-1
expression, which in parallel with the re-appearance of
PrP
Sc, increased at days 3 and 4 post transfection as
demonstrated by immunoblot analysis (Suppl. Fig. 1a).
In summary, efﬁcient knock-down of NPC-1 by siRNA
leads to a signiﬁcant transient reduction of PrP
Sc in ScN2a
cells.
U18666A treatment reduces PrP
Sc in persistently
infected cells but does not inhibit primary infection
Similar to NPC-1 knock-down, cholesterol accumulation
in late endosomes/lysosomes can be induced by treat-
ment with the negatively charged amine U18666A.
Unfortunately, the targets of U18666A have not been
characterized so far, and therefore the exact mechanism of
action of this drug is unknown [34]. It was suggested that
the compound acts directly on the NPC-1 pathway to
induce lysosomal accumulation of cholesterol [37], and, in
addition, inhibits an enzyme of the cholesterol synthesis
pathway [43]. Since cholesterol accumulation induced by
U18666A is well documented and the drug is commonly
used to induce an NPC phenotype in cultured cells
[36–38], we employed the compound in our further
experiments. First, we investigated whether the effects of
NPC-1 knock-down on cellular PrP
Sc content are repro-
duced by U18666A treatment. ScN2a cells were treated
for 3 days with increasing concentrations of U18666A
(0, 1, 3, or 5 lg/ml, a range which is frequently used to
induce cholesterol storage within several hours) [19, 34,
37]. Samples with or without PK digestion were analyzed
by immunoblot for PrP signals (Fig. 2a). In untreated
cells, a strong PrP
Sc signal was visible (lane 2), which was
signiﬁcantly reduced by 1 lg/ml of U18666A (lane 4) and
undetectable by 3 (lane 6) or 5 lg/ml (lane 8) of the drug.
The amount of PrP
c was not signiﬁcantly inﬂuenced by
the treatment (lanes — PK, total PrP). In addition, ScN2a
cells were treated with 0 or 3 lg/ml U18666A for 3 and
7 days. To enable comparison of signals in treated and
untreated cells, for each time point one control culture
was lysed in parallel. Aliquots with or without PK treat-
ment were subjected to immunoblot (Fig. 2b). Again,
PrP
Sc was reduced to undetectable levels, whereas in
untreated control cells, a clear PrP
Sc signal was visible
(lanes ? PK). The increase in PrP
Sc signals between day
3 and day 7 in control cells is indicative for accumulation
of PrP
Sc during cultivation. PrP
c levels were not altered
by the treatment (lanes — PK). A similar reduction of
PrP
Sc by U18666A treatment was observed in N2a cells
infected with prion strain 22L (data not shown).
In order to verify that the observed effects on PrP
Sc
generation were not speciﬁc for ScN2a cells, two further
prion-infected cell lines were tested, namely ScGT-1
(Suppl. Fig. 2a) and ScSN56 (Suppl. Fig. 2b) cells. These
cells were treated with lower concentrations of the drug for
3 (ScSN56) or 8 days (ScGT-1). In these cell lines, the
anti-prion effect of U18666A could be conﬁrmed. Of note,
toxicity of the compound was excluded in all three cell
lines by XTT assay for the concentrations and durations of
treatment chosen for this study (data not shown).
The next question was whether the presence of
U18666A during primary prion infection can inhibit the
establishment of persistent infection (Fig. 2c). 3F4-N2a
cells susceptible to infection were left untreated or were
pre-treated for 4 h with U18666A (3 lg/ml). Subsequently,
brain homogenates from terminally sick mice infected with
RML or 22L prions were added for 24 h. During infection,
cells were either left untreated (-) or U18666A was added
during the 24 h of brain homogenate incubation (?) or the
pre-treatment was continued for the infection period
(?4; 28 h treatment in total). After removal of brain
homogenates and drug, cells were further passaged. Pas-
sage 3 was lysed and a solubility assay of cell lysates with
or without PK digestion was performed. Insoluble fractions
of samples ? PK (P/? PK; lanes 1–6) harboring PrP
Sc and
supernatant fractions of samples — PK (S/–PK; lanes
7–12) containing soluble PrP
c were subjected to immuno-
blot analysis. To selectively detect newly converted PrP
Sc,
mAb 3F4 was used. Independent of treatment and prion
strain, all cell cultures harbored high amounts of 3F4-
positive PrP
Sc, indicative of primary prion infection.
In summary, similar to the NPC-1 knock-down, treat-
ment with U18666A reduces PrP
Sc content in persistently
infected ScN2a, ScGT-1, and ScSN56 cells. However,
primary infection of 3F4-N2a cells was not inhibited by the
drug.
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association are not perturbed by U18666A
Frequently, the mode of action of PrP
Sc-reducing com-
pounds in cell culture is an altered localization or turnover
of PrP
c that does not necessarily implicate an altered signal
for total PrP
c content as detected by immunoblot [44]. In
particular, perturbation of cellular cholesterol metabolism
might inﬂuence PrP
c transport to the plasma membrane or
its localization in lipid rafts.
To exclude such effects, the subcellular localization of
PrP
c in U18666A-treated cells was investigated. N2a cells
were treated for 3 days with U18666A. Subsequently, PIP-
LC digestion was performed, which releases GPI-anchored
proteins from the cell surface. In both U18666A-treated and
untreated cells, PrP
c was undetectable in cell lysates after
PIPLC treatment (Fig. 3a; lanes 2 and 4), indicating that
PrP
c plasma membrane localization was not impaired by
U18666A. This was conﬁrmed by immunoﬂuorescence
assay performed with U18666A-treated or untreated N2a
cells (Fig. 3b). Again, under both conditions PrP
c was
clearly detectable at the cell surface.
Next, we tested whether the turnover of PrP
c at the cell
surface was changed by U18666A treatment. N2a cells
were treated with U18666A or were left untreated for
control, and biotinylation of cell surface proteins was
performed. The amounts of total (-trypsin) and internal-
ized (?trypsin) PrP
c were analyzed by immunoblot.
Figure 3c shows a representative immunoblot of several
independent experiments. At 0 min, almost all PrP
c could
be released by trypsin indicating that the majority of PrP
c
was located at the cell surface and only small amounts were
already internalized (lanes 2 and 4). After 60 min, in
control cells slightly less PrP
c than in U18666A-treated
cells was accessible for trypsin, indicating that more PrP
c
Fig. 2 Dose- and time-dependent reduction of PrP
Sc in persistently
infected cells, but no inhibition of primary infection upon chemical
induction of lysosomal cholesterol accumulation. a ScN2a cells were
treated for 3 days with various concentrations (0, 1, 3, or 5 lg/ml) of
U18666A as indicated. Cells were lysed, digested with PK (?PK)o r
not (-PK), and proteins were analyzed by immunoblot. Mab 4H11
was used for detection of PrP-speciﬁc bands. The immunoblot was
dehybridized and incubated with an anti-b-actin mAb to control for
equal loading (lower panel). b Treatment of ScN2a cells with
U18666A (3 lg/ml) was performed for 3 and 7 days in parallel to
mock treatment. At the different time points, U18666A-treated and
mock-treated cells were lysed. Lysates were digested with PK (?PK)
or not (-PK) and were subjected to immunoblot analysis using mAb
4H11. Equal loading of lysates of the different time points was
conﬁrmed by reprobing the membrane with anti-b-actin mAb (lower
panel). c 3F4-N2a cells were left untreated or were pretreated for 4 h
with U18666A (3 lg/ml) prior to prion infection. For prion infection,
brain homogenates (1%) from RML- or 22L-infected terminally sick
mice were added for 24 h to the culture medium. Cells that had
not been pretreated were infected either in the presence (?)o r
absence (-) of U18666A for 24 h. For pretreated cells, the U18666A
treatment was continued for the time period of infection (?4; 28 h
treatment in total). After 24 h, brain homogenates and U18666A were
removed, cells were washed and passaged three times 1:10. Passage 3
was lysed, lysates were treated with PK (?PK) or left untreated
(-PK) and were then subjected to a solubility assay. Pellet fractions
of samples ? PK (P/?PK) and supernatant fractions of samples -PK
(S/-PK) were analyzed by immunoblot with mAb 3F4, which
selectively detects newly generated 3F4-PrP
Sc in the pellet fractions
(P/?PK) and 3F4-PrP
c in the supernatant (S/-PK)
c
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Densitometric analysis revealed that in control cells *55%
of total PrP
c was internalized, whereas in U18666A-treated
cells only *35% was found within the cells. However, this
difference was not statistically signiﬁcant (Fig. 3c).
Alterations in cholesterol metabolism may implicate
that lipid raft assembly or localization of proteins in these
membrane domains is disturbed. To verify this, detergent-
resistant microdomains were isolated, and ﬂotation assays
were performed with U18666A-treated or untreated N2a
cells (Fig. 4). Fractions of the gradients were collected and
analyzed by immunoblot (Fig. 4a). Without treatment
(-U18666A), the majority of PrP
c partitioned in fractions
3 and 4, which correlates with the presence of the lipid raft
marker GM1 in these fractions (Fig. 4b). In treated cells
(?U18666A), localization of PrP
c signals again correlated
with GM1 signals. However, peak levels were shifted from
fractions 3 and 4 in untreated cells to fraction 2.
These data indicate that U18666A treatment has no
major detectable effects on PrP
c endocytosis and/or recy-
cling. Despite drug treatment, it is localized within
detergent-resistant membrane domains.
No inﬂuence of U18666A treatment on cellular de novo
generation of PrP
Sc
Our data obtained so far demonstrate that alterations in
PrP
c plasma membrane localization are probably not
responsible for the observed reduction of PrP
Sc levels in
ScN2a cells upon U18666A treatment. Since cholesterol
accumulation upon NPC-1 knock-down or U18666A
treatment occurs in late endosomes/lysosomes, cell bio-
logical effects induced by the treatments are likely exerted
in the late endocytic pathway.
Fig. 3 No changes in membrane localization and turn-over of PrP
c in
U18666A treated N2a cells. a N2a cells were treated for 3 days with
U18666A (3 lg/ml) or left untreated as indicated. For release of PrP
c
by PIPLC (left panel), cells were incubated for 4 h with or without the
enzyme. Treatment with U18666A was continued during PIPLC
digestion. Then cells were lysed and lysates were subjected to
immunoblot analysis using mAb 4H11for detection of PrP speciﬁc
bands. b N2a cells with or without U18666A treatment for 3 days
were ﬁxed, permeabilized, and stained in indirect immunoﬂuores-
cence with anti-PrP mAb 4H11 and Cy2-conjugated anti-mouse IgG.
c Biotinylation of N2a cells treated for 2 days with or without
U18666A was performed and cultures were chased at 37C in culture
medium -/?U18666A for 60 min or were processed immediately.
After 0 or 60 min chase, one culture dish each of treated or untreated
cells was incubated with trypsin. PrP from cell lysates was
immunoprecipitated using pAb A7, subjected to immunoblot, and
detected by incubation with horseradish peroxidase (HRP)-conjugated
streptavidin. A representative immunoblot of three independent
experiments is shown. PrP
c signals of the 60 min time point with
(internalized PrP
c) or without (total PrP
c) trypsin digestion were
densitometrically analyzed. The amount of internalized PrP
c was
expressed as a percentage of total PrP
c. The lower panel depicts
statistical evaluation of the difference between internalized PrP
c in
mock-treated or U18666A-treated cells using Student’s t-test (ns not
signiﬁcant; P-value[0.05; bars indicate standard error)
Fig. 4 Lipid raft association of PrP
c is not altered in U18666A-
treated cells. a N2a cells were treated for 3 days with U18666A (right
panel) or left untreated (left panel) and were subjected to a ﬂotation
assay. Ten fractions from the top to the bottom of the centrifuge tube
were collected and analyzed by immunoblot with mAb 4H11.
b Aliquots of gradient fractions were spotted on a nitrocellulose
membrane and GM1 was detected by incubation of the membrane
with HRP-conjugated cholera toxin subunit B (CtxB)
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baﬁlomycin A (Baf A) and U18666A treatment—PrP
Sc can
be detected in ScN2a cells. Baﬁlomycin A prevents protein
transport from early to late endosomes by inhibiting acidi-
ﬁcation and maturation of those vesicles. Thereby, the
degradation of proteins is prevented. The combined treat-
ment might give hints to whether U18666A prevents
synthesis of PrP
Sc or rather induces its degradation. ScN2a
cells were treated for 24 h with U18666A or left untreated.
Then cells were lysed and lysates were digested with PK. In
parallel, in ScN2a cultures, U18666A treatment was con-
tinued for 2 days, either in combination with Baf A or not.
Untreated cells and cells treated only with Baf A served as
controls. PK-treated lysates were analyzed in immunoblot
(Fig. 5upperpanel;duplicateassay).After24 h(lanes1–4),
PrP
Sc was detectable in controls but not in U18666A-treated
cells. These PrP
Sc signals served as baseline levels for
comparison with PrP
Sc signal intensities after continued
cultivation either without treatment (lanes 5 and 6), with
U18666A (lanes 7 an 8) or Baf A (lanes 9 and 10) alone, or
with a combination of U18666A and Baf A (lanes 11 and
12). Upon continued culture (day 3), in control cells without
treatmentastrongPrP
Scsignalwasvisiblewhichwasclearly
higher than that at day 1 (lanes 5 and 6 vs. lanes 1 and 2). As
expected,inU18666A treated cells (lanes7and8)thesignal
again was lower than in untreated cells. However, Baf A
treatment led to a strong increase of PrP
Sc signals in both
controls(lanes9and10)andU18666A-treated(lanes11and
12)cellsduetoimpaireddegradationofPrP
Scbetweenday1
and day 3. This indicates that despite cholesterol accumu-
lation in endosomal vesicles, PrP
Sc can be formed. In case
the Baf A treatment were to only inhibit degradation of pre-
existing PrP
Sc, the signal after 3 days would not exceed the
initial signal after 1 day treatment (compare lanes 3 and 4 to
lanes11and12).Analysisofcorrespondingsampleswithout
PK digestion (Fig. 5 lower panel) with anti-b-actinand anti-
PrP antibodies served as control for comparable loading at
the different time points. The increase in PrP
c and PrP
Sc
signals between day 1 and day 3 is due to higher cell num-
bers and accumulation of PrP
Sc which is newly formed
between day 1 and day 3. A further hint for ongoing gen-
eration of PrP
Sc in U18666A-treated cells was provided by
metabolic labeling of ScN2a cells followed by immuno-
precipitation of PrP
Sc (data not shown).
In summary, these data demonstrate that PrP
Sc can be
formed in U18666A-treated cells and that the treatment
rather enhances degradation of PrP
Sc.
Rab 9 overexpression partially restores PrP
Sc contents
in U18666A-treated cells
It has been demonstrated previously that cholesterol
accumulation in late endosomal/lysosomal compartments
can be attenuated by overexpression of rab 9 [45], impli-
cating that this might alleviate the negative inﬂuence of
U18666A on PrP
Sc propagation. To verify this hypothesis,
an EGFP-rab 9 fusion protein was transiently overexpres-
sed in U18666A-treated and untreated ScN2a cells. FACS
analysis of cells expressing EGFP-rab 9 revealed a trans-
fection efﬁciency of *70% (data not shown). As controls,
ScN2a cells were transfected with empty vector. One day
post transfection, U18666A was added for 2 days. Samples
of PK-digested lysates were subjected to immunoblot
analysis. Figure 6 shows a representative experiment per-
formed in duplicate. Control cells (pcDNA3.1) harbored
high amounts of PrP
Sc, which were diminished by
U18666A treatment (left panel). Surprisingly, rab 9 over-
expression appeared to reduce PrP
Sc levels when compared
to cells transfected with empty vector even without
U18666A treatment (middle panel). However, the differ-
ence in PrP
Sc signals between untreated and treated cells
overexpressing EGFP-rab 9 (right panel; the inlet depicts
EGFP-rab 9 overexpression) appeared to be less pro-
nounced than the one observed between mock-transfected
controls with or without U18666A treatment (left panel).
To illustrate this, quantiﬁcation of ﬁve independent
experiments was done for statistical analysis (Fig. 6; lower
Fig. 5 U18666A treatment increases PrP
Sc degradation. Upper panel
ScN2a cells were treated for 1 day with U18666A (3 lg/ml) or were
left untreated. Cells were either lysed after 1 day and lysates were
treated with PK (lanes 1–4) or were incubated for further 2 days (day
3; lanes 5–12) with or without U18666A in presence or absence of
baﬁlomycin A (10 nM). Then cells were lysed and subjected to PK
digestion. All samples were separated by SDS-PAGE followed by
immunoblot. For detection of PrP, mAb 4H11 was used. The
experiment was performed in duplicate. Lower panel Samples without
PK digestion were analyzed by immunoblot for total PrP using mAb
4H11 and for b-actin levels (arrow) for control of equal loading
3986 S. Gilch et al.panel). Both the differences in PrP
Sc signals between
control cells with U18666A (P \ 0.005) and between
control and rab 9-expressing cells (P\ 0.05) were statis-
tically signiﬁcant. In contrast, the signal reduction between
rab 9-overexpressing cells treated with U18666A compared
to nontreated cells was not signiﬁcant (P = 0.183).
This indicates that although rab 9 overexpression redu-
ces PrP
Sc in ScN2a cells, it can attenuate the reduction of
PrP
Sc content in ScN2a cells induced by cholesterol
accumulation in the late endocytic pathway.
Discussion
Cholesterol is an important constituent of biological
membranes and is concentrated in lipid rafts together with
sphingolipids. Depletion of cholesterol impairs cellular
prion conversion, and the study presented here was inten-
ded to investigate the impact of cholesterol accumulation in
late endosomes on PrP
Sc propagation in persistently prion-
infected cells and on primary prion infection.
LDL-cholesterol, which is internalized via the LDL-
receptor, dissociates in endosomes, and both cholesterol and
the LDL-receptor recycle back to the plasma membrane.
Two proteins implicated in cholesterol recycling are NPC-1
and NPC-2. Loss-of-function mutations—mainly in the
NPC-1, but also in the NPC-2 gene—are associated with
Niemann-Pick type C disease (NPC), a neurodegenerative
disorder characterized by excessive cholesterol accumula-
tion in late endosomes and lysosomes [45, 46]. In ScN2a
cellswefoundthatknock-downofNPC-1ledtoadrasticloss
ofPrP
Sc.Similareffects,alsoin22Lprion-infectedN2acells
(data not shown), ScGT-1, and ScSN56 cells were obtained
by treatment with the compound U18666A. This is in
agreementwithpreviousﬁndings[47,48],however,thedrug
appearsnottobeeffectiveinamousemodelofpriondisease
[48]. In both studies, signiﬁcantly lower concentrations of
thedrugwereusedtodeterminetheIC50valueover4 daysof
treatment,afactorwhichiscriticalifadrugwillbeappliedin
bioassays [47, 48]. In contrast, our main intention was to
induce cholesterol accumulation within a short time frame
(16 h to 2 days). Therefore, we applied higher concentra-
tions of the drug as described in previous publications [19,
34, 37] which were not toxic to the cells under our experi-
mental conditions to achieve the NPC phenotype. However,
U18666A treatment, which phenocopies NPC, does not
exclusively inhibit cholesterol recycling within the cell but
also to some extent the endogenous cholesterol synthesis
Fig. 6 Rab 9 overexpression impairs PrP
Sc propagation but partially
rescues the interference induced by cholesterol accumulation. ScN2a
cells were transiently transfected with pEGFP-rab 9 or with
pcDNA3.1 as a control. Following transfection, treatment with
U18666A (3 lg/ml) was performed for 2 days. Then cells were
lysed, aliquots were digested with PK, and samples were analyzed by
immunoblot using mAb 4H11. A representative duplicate experiment
is shown (upper panel). To enable better comparison, samples
analyzed by one immunoblot were opposed to each other. Expression
of EGFP-rab 9 was detected using a polyclonal anti-GFP antibody.
PrP
Sc signals of ﬁve independent experiments were evaluated
densitometrically (ImageQuant TL), and statistical analysis was
performed (lower panel, ns not signiﬁcant; *P \0.05, **P \0.005;
bars indicate standard error). The signal intensity of untreated mock-
transfected controls was set as 100%, and all other values are
expressed as a percentage of this value
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data obtained with siRNA targeting NPC-1 mRNA clearly
demonstrate that indeed cholesterol accumulation can cause
reduction of PrP
Sc in ScN2a cells. Interestingly, primary
infection of N2a cells with RML or 22L prions was not
inhibited by U18666A. This indicates that initial conversion
of PrP
c to PrP
Sc might occur even under conditions of cho-
lesterol accumulation. However, this initial conversion rate
appeared to be insufﬁcient for establishing persistent prion
infection when U18666A treatment was continued after
removal of brain homogenates (data not shown).
Our results on PrP
c localization and trafﬁcking support
the assumption that formation of PrP
Sc can occur during
U18666A treatment. PrP
c is located at the cell surface,
which is one prerequisite for conversion into PrP
Sc, and its
recycling is at least not statistically signiﬁcantly altered.
PrP
c is still found in lipid rafts, in contrast to what has been
suggested previously [47]. The ﬁnding that lipid raft for-
mation is not perturbed by U18666A treatment is supported
by studies demonstrating that lipid rafts are stabilized in late
endosomes in U18666A-treated cells [34] or even accumu-
late in cells expressing mutated NPC-1 [33]. It is interesting
to note that a shift of the raft marker protein caveolin-1
towards lighter fractions of a ﬂotation gradient, which we
observed for GM-1 and PrP
c in U18666A-treated cells, was
induced by infection of a ﬁbroblast cell line with a murine
parvovirus [49]. These alterations led to an increased uptake
of PrP
Sc compared to controls without changing its subcel-
lular distribution [49]. The observation that trafﬁcking of
exogenously added PrP
Sc is not altered under such condi-
tions supports the plausibility of our ﬁnding that despite
slight alterations of lipid rafts induced by U18666A treat-
ment, primary infections of N2a cells can be established.
Compounds targeting cholesterol homeostasis previ-
ously found to be active against PrP
Sc formation in cell
culture mainly affected the pool of plasma membrane
cholesterol and/or lipid raft formation [20, 22, 24–26]. In
contrast, by inducing a NPC phenotype in cultured cells,
alterations are expected to occur mainly in late endosomal
or lysosomal compartments. That perturbations of PrP
Sc
propagation are indeed occurring in the late endosomal/
lysosomal system is shown by our experiments with
co-treatment of cells with U18666A and baﬁlomycin
A. Baﬁlomycin A inhibits protein degradation, since early
to late endosome maturation is impaired due to perturba-
tion of endosomal acidiﬁcation. However, recycling of
early endosomes and their cargo proteins to the plasma
membrane is still possible [50]. Upon combined treatment
with U18666A and Baf A, which inhibits lysosomal deg-
radation, between day 1 and 3 PrP
Sc signals increased
(Fig. 5a; lanes 3 and 4 vs. lanes 11 and 12). This demon-
strates that, in principle, PrP
Sc can be generated during
U18666A treatment, but that increased degradation inhibits
its accumulation. This is feasible since RML PrP
Sc in
infected cells might propagate in early endosomes or at the
plasma membrane [51], both pathways that are not
impaired by Baf A. To elucidate whether recycling from
early endosomes to the plasma membrane is important for
PrP
Sc propagation requires further experiments and is
beyond the scope of this study. However, PrP
Sc formation
is increased in RML-infected N2a cells overexpressing a
transdominant negative rab4 mutant [52]; therefore this
pathway seems to be dispensable for PrP
Sc propagation.
Overall, our data suggest that upon U18666A-induced
cholesterol accumulation in the late endosomal/lysosomal
compartment degradation of PrP
Sc is accelerated. Indeed,
the drug can stimulate cellular autophagy [53], a pathway
that contributes to the degradation of misfolded protein,
e.g., of huntingtin aggregates associated with Huntington’s
disease [54]. Interestingly, two novel studies demonstrate
that induction of autophagy can stimulate the degradation
of PrP
Sc in prion-infected cells [55, 56]. In NPC-/- mice
levels and activity of cathepsin D and B are increased [57].
PrP
Sc accumulates in late endosomes [58] and lysosomes
[59], where it can be degraded, although it has a rather long
half-life of more than 24 h [39, 60]. In particular, lyso-
somal cystein proteases such as cathepsin B and L are
capable of degrading PrP
Sc [61, 62], and induction of their
activity by inducing a NPC phenotype could also account
for improved degradation of PrP
Sc.
Impairment of cholesterol transport by NPC-1 knock-
down is accompanied by disturbances in vesicle trafﬁcking
due to immobilization of rab GTPases [45, 63], which
regulate vesicle trafﬁcking and docking to their speciﬁc
target organelle membranes [64]. In NPC-/- ﬁbroblasts or
U18666A-treated cells accumulation of cholesterol in late
endosomes can be alleviated by overexpression of rab 9,
which increases delivery of cholesterol-laden vesicles and
their cargo to the Golgi/TGN and thereby induces redis-
tribution of cholesterol [45, 65]. In ScN2a cells treated with
U18666A, we observed that rab 9 overexpression partially
rescued PrP
Sc propagation. This indicates that cholesterol
and/or vesicle recycling to the TGN is necessary for PrP
Sc
propagation. Furthermore, PrP
Sc located within late endo-
somes might be transported via rab 9-positive vesicles to
the Golgi/TGN. Thereby, a certain escape from degrada-
tion could be achieved, explaining the partial rescue of the
negative U18666A effects. Surprisingly, we found that rab
9 overexpression alone signiﬁcantly impaired PrP
Sc prop-
agation. This apparently contradictory ﬁnding might be
comparable to the relation between amyloid b-peptide (Ab)
production and expression levels of the sorting protein-
related receptor sorLA. Upon overexpression of this pro-
tein, redistribution of amyloid precursor protein (APP) to
the Golgi complex is induced, thereby protecting APP from
processing to Ab [66]. For PrP
Sc, a similar balance between
3988 S. Gilch et al.new formation and residence time in certain compartments
might exist that could explain, on the one hand, the positive
effects in U18666A-treated cells, and, on the other hand,
the negative effects of rab 9 overexpression in untreated
cells on PrP
Sc propagation.
Altogether, our study demonstrates that accumulation of
cholesterol in the late endocytic pathway is deleterious for
PrP
Sc propagation in cultured cells. Rather than perturba-
tion of lipid raft association, we suggest that an increased
degradation of PrP
Sc is responsible for this effect.
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